Europe, Middle East and Africa Gastrointestinal Drugs Market Research Report - Forecast to 2027

Europe, Middle East and Africa Gastrointestinal Drugs Market Research Report, by Drug Category (Acid Neutralizers, Laxatives and Antidiarrheal, Anti-inflammatory drugs), By Route of Administration (Oral, Parenteral, Rectal), By Disease Type (Gastroesophageal Reflux Disease, Inflammatory Bowel Disease), by end user (Hospital Pharmacies, Retail Pharmacies) - Forecast till 2027

ID: MRFR/Pharma/0165-HCR | February 2021 | Region: Middle East & Africa | 85 pages

Please note that the assessment period of report has been updated from 2017-2023 to 2020-2027. Cordially fill the sample form for updated data.

Market Scenario:
Gastrointestinal (GI) drug market is a growing market in Europe and Middle East and Africa. As per study it was estimated that ~ 6% of total European population is suffering from minor or major gastrointestinal problems. Gastroesophageal reflux is the most common disease and is responsible for generating a good market. The major driving factor for this market are increasing prevalence of many gastrointestinal disease. In addition to this, technological advances, infrastructure development increasing investment in research activity and increasing awareness about the availability of treatment are responsible for providing fuel for the growth of the market. While incorrect self-diagnosis and availability of many misbranded drug are the major restraining factor for the growth of market.
Study Objectives Europe, Middle East and Africa Gastrointestinal Drugs Market Research Report



  • Market Analysis of Europe, Middle East and Africa Gastrointestinal Drugs Market, with region assessment and competitive analysis.

  • Detail market identification with its drivers and restrain of the market.

  • To provide thorough understanding of various segment and sub segments of the market.

  • Analysis of market on the basis of different factors like price analysis, supply chain analysis, porters five force analysis etc.

  • To provide historical and forecast revenue of the market segments and sub-segments with respect to their main geographies and their countries

  • To track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the Europe, Middle East and Africa Gastrointestinal Drugs Market.

  • Information about the key companies that may influence this market in this region.


Figure 1- Europe, Middle East and Africa Gastrointestinal Drugs Market, by Disease type
Europe Gastrointestinal Drugs Market-


Europe and Middle East and Africa GI drug market is expected to grow at a CAGR of 4.5% during 2017-2023.


Key Players for Europe, Middle East and Africa Gastrointestinal Drugs market

AstraZeneca Plc.(UK), Johnson & Johnson (US), Takeda Pharmaceutical Company Limited (Japan), Eisai Co., Ltd. (Japan), Valeant Pharmaceuticals Inc. (US), Sanofi Ltd. (France), Valeant (US), Abbott Laboratories(US), Allergan Plc (US), Bayer AG (Germany), Janssen Biotech Inc. (US), AbbVie Inc. (US), Janssen Biotech (US), GlaxoSmithKline Plc. (UK), Boehringer Ingelheim GmbH (Germany).

Segmentation
Europe, Middle East and Africa gastrointestinal drugs market has been segmented on the basis of Drug Category they are segmented into Acid Neutralizers, Laxatives and Antidiarrheal, antiemetic, Anti-inflammatory drugs and other. Acid Neutralizers are further sub segmented into Antacids, H2 antagonists, Proton pump inhibitors and others. By Route of Administration they are segmented into Oral, Parenteral and rectal. By disease type they are segmented into Gastroesophageal Reflux Disease, Inflammatory Bowel Disease and Other. By End User Hospital Pharmacies, Retail Pharmacies and Other


Research Methodology
Europe Gastrointestinal Drugs Market
Regional Analysis
Europe is the second major contributor in the GI drug market globally. Total Europe and Middle East and Africa GI drug market in 2016 was approximately USD$ 15 million. Germany and France are the major contributor of the market this is due to a huge number of patient suffering from different GI problems. About 9.2% of total population in France is suffering from acute or chronic GI problems. This is the major factor responsible for the growth of market. Due to saturation of market in this region the market is growing at a steady CAGR of 4.5 % during 2017-2023.


The report for Europe, Middle East and Africa Gastrointestinal Drugs Market of Market Research Future comprises of extensive primary research along with the detailed analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain the deeper insight of the market and industry performance. The report gives the clear picture of current market scenario which includes historical and projected market size in terms of value and volume, technological advancement, macro economical and governing factors in the market. The report provides details information and strategies of the top key players in the industry. The report also gives a broad study of the different markets segments and regions.


 Intended Audience



  • Manufacturing industries.

  • Pharmaceutical industry.

  • Biotechnology Companies

  • Research and Development (R&D) Companies 



TABLE OF CONTENTS
1 INTRODUCTION

1.1 DEFINITION

1.2 SCOPE OF STUDY

1.2.1 RESEARCH OBJECTIVE

1.2.2 ASSUMPTIONS & LIMITATIONS

1.2.2.1 ASSUMPTIONS

1.2.2.2 LIMITATIONS

1.3 MARKET STRUCTURE:

2 RESEARCH METHODOLOGY

2.1 RESEARCH PROCESS:

2.2 PRIMARY RESEARCH

2.3 SECONDARY RESEARCH:

3 MARKET DYNAMICS

3.1 DRIVERS

3.2 RESTRAINTS

3.3 OPPORTUNITIES

3.4 MACROECONOMIC INDICATORS

4 MARKET FACTOR ANALYSIS

4.1 PORTERS FIVE FORCES MODEL

4.2 BARGAINING POWER OF SUPPLIERS

4.3 BARGAINING POWER OF BUYERS

4.4 THREAT OF NEW ENTRANTS

4.5 THREAT OF SUBSTITUTES

4.6 INTENSITY OF RIVALRY

5. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY DRUG CATEGORY

5.1 ACID NEUTRALIZERS

5.1.1 ANTACIDS

5.1.2 H2 ANTAGONISTS

5.1.3 PROTON PUMP INHIBITORS

5.1.4 OTHERS

5.2 LAXATIVES AND ANTIDIARRHEAL

5.3 ANTIEMETIC

5.4 ANTI-INFLAMMATORY DRUGS

5.5 OTHER

6. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY ROUTE OF ADMINISTRATION

6.1 ORAL

6.2 PARENTERAL

6.3 RECTAL

7. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, DISEASE TYPE

7.1 GASTROESOPHAGEAL REFLUX DISEASE

7.2 INFLAMMATORY BOWEL DISEASE

7.3 OTHER

8 EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET

8.1 HOSPITAL PHARMACIES

8.2 RETAIL PHARMACIES

8.3 OTHER

9. EUROPE, MIDDLE EAST AND AFRICA GASTROINTESTINAL DRUGS MARKET, BY REGION

9.1 INTRODUCTION

9.2 EUROPE

9.2.1 WESTERN EUROPE

9.2.1.1 GERMANY

9.2.1.2 FRANCE

9.2.1.3 ITALY

9.2.1.3 SPAIN

9.2.1.5 UK

9.2.1.6 REST OF WESTERN EUROPE

9.2.2 EASTERN EUROPE

9.3 MIDDLE EAST & AFRICA

10. COMPETITIVE LANDSCAPE

10.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS

10.1.1 STRATEGIC PARTNERSHIP

10.1.2 MERGER & ACQUISITION

11 COMPANY PROFILE

11.1 ABBVIE INC.

11.1.1 OVERVIEW

11.1.2 PRODUCT OVERVIEW

11.1.3 FINANCIALS

11.1.4 KEY DEVELOPMENTS

11.2 ASTRAZENECA

11.2.1 OVERVIEW

11.2.2 PRODUCT OVERVIEW

11.2.3 FINANCIALS

11.2.4 KEY DEVELOPMENTS

11.3 JOHNSON & JOHNSON

11.3.1 OVERVIEW

11.3.2 PRODUCT OVERVIEW

11.3.3 FINANCIALS

11.3.4 STRATEGY

11.3.5 KEY DEVELOPMENT

11.4 TAKEDA PHARMACEUTICAL COMPANY LIMITED

11.4.1 OVERVIEW

11.4.2 PRODUCT OVERVIEW

11.4.3 FINANCIALS

11.4.4 KEY DEVELOPMENTS

11.5 ALLERGAN PLC

11.5.1 OVERVIEW

11.5.2 PRODUCT OVERVIEW

11.5.3 FINANCIALS

11.5.4 KEY DEVELOPMENTS

11.6 OTHERS